Stockwinners Market Radar for November 07, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:37 EST Associated Banc-Corp cuts prime rate to 7.75% - Associated Banc announced it has decreased the bank's prime rate from 8.00% percent to 7.75% percent, effective November 8, 2024.

20:03 EST Cathie Wood's ARK Investment bought 94.4K shares of Absci today

19:50 EST XChange TEC.INC (ADR) trading halted, news pending

18:58 EST Webster Financial lowers prime lending rate to 7.75% - Webster Financial announced that it has lowered its prime lending rate to 7.75% from 8.00%, effective November 8, 2024.

18:53 EST SkyWest CFO sells $1.73M in common stock - In a regulatory filing, SkyWest disclosed that its CFO Robert Simmons sold 16.5K shares of common stock on November 5th in a total transaction size of $1.73M.

18:48 EST Cytek Biosciences introduces ESP Detection Option for Cytek Aurora - Cytek Biosciences has introduced an Enhanced Small Particle, or ESP, Detection Option for its Cytek Aurora CS system. This is the first commercially available small particle detector on a cell sorter and offers a significant advancement for rapidly evolving research fields, including in drug delivery, cell therapy, disease diagnostics, circulating tumor cells, regenerative medicine, and vaccine delivery. Researchers can now achieve downstream analysis of materials that were previously unable to be sorted, opening new possibilities for breakthroughs in these areas.

18:44 EST Weatherford awarded three-year contract - Weatherford announced that it has been awarded a three-year contract for the provision of rigless services as part of the reactivation of ADNOC onshore strings. The project is slated to begin in the fourth quarter of 2024, where Weatherford is expected to deploy multiple intervention solutions, advancing the operational efficiency and reliability of ADNOC's onshore assets.

18:42 EST Vision Marine Technologies regains Nasdaq compliance - Vision Marine Technologies is pleased to announce that the company received a compliance notice from the Nasdaq Hearing Panel informing the company that it has regained compliance with the bid price requirement under Nasdaq Listing Rule 5550(a)(2). This compliance fulfils the requirements outlined by the Panel in its decision dated October 3.

18:38 EST Lantronix to acquire NetComm Wireless enterprise IoT portfolio for $6.5M - Lantronix announced that it has signed a definitive agreement to acquire from NetComm Wireless, a subsidiary of DZS, Inc., all of the assets of its enterprise Internet of Things business for $6.5M in cash together with assumptions of certain liabilities. The closing of the acquisition is subject to certain conditions. Lantronix believes that the transaction will close during the second quarter of fiscal 2025. Lantronix expects the acquisition to be accretive upon closing and will accelerate the company's strategic focus on innovative Industrial IoT solutions at scale. By integrating this new IoT portfolio, Lantronix will enhance its connectivity solutions in mission-critical areas, such as critical infrastructure, asset monitoring and telecommunications.

18:34 EST AMC Entertainment announces Go Plan to invest up to $1.5B - AMC Entertainment announced AMC's Go Plan, through which AMC expects to invest between $1B and $1.5B over the next four to seven years, enhancing its locations in the United States and Europe. With AMC's Go Plan, AMC will provide guests with a greater selection of premium experiences, immersive sight & sound enhancements, more comfortable seating and upgraded theatres, as well as other initiatives. In addition to recent and current renovations at AMC flagship locations like AMC Lincoln Square 13 & AMC Empire 25 in New York, and AMC Burbank 16 in Los Angeles, AMC has a list of theatres that could receive significant seating and other upgrades as part of AMC's Go Plan. Similarly, for ODEON Cinemas in Europe, there are opportunities to develop a meaningful number of additional Luxe Cinemas, especially in the UK. Through AMC's Go Plan, AMC expects to expand its premium large format and extra-large format offerings, as well as expand the number of Laser at AMC auditoriums. The timing and extent of AMC's Go plan will be calibrated according to the box office recovery trajectory and AMC's available capital, liquidity levels, and leverage ratios.

17:31 EST Northern Trust cuts prime rate to 7.75% - Northern Trust has decreased its prime rate from 8.00% to 7.75%, effective Friday, November 8, 2024.

17:27 EST Trinity Capital authorizes stock repurchase program - Trinity Capital has authorized a program for the purpose of repurchasing up to $30M worth of the company's common stock. Unless amended or extended, the company expects the repurchase program to be in place until the earlier of November 7, 2025, or until $30M of Trinity's outstanding shares of common stock have been repurchased.

17:22 EST QuidelOrtho sees cost-savings of at least $50M in 2H24 - Sees 2H and FY24 positive adjusted free cash flow to exceed 50% of adjusted EBITDA, including full year interest expense of $160M-$165M and CapEx of ~$170M, excluding reagent rentals.

17:13 EST QuidelOrtho says China continues to be a 'complex market' - Sees "more potential upside than risk" in China.

17:10 EST RingCentral, Verint announce strategic partnership - RingCentral (RNG) and Verint (VRNT) announced a strategic partnership to provide RingCX customers access to best-in-class workforce engagement management and CX automation. Through this partnership, RingCX customers will have more choice and be able to leverage Verint's leading WEM and CX automation solutions, which complement RingCentral's native AI capabilities, to enhance employee productivity and improve customer experiences, ultimately driving competitive advantage and operational efficiency. "We've seen strong traction in all segments of the market, and to further enhance the value proposition of RingCX in the mid and enterprise segments, we see integration with Verint as a key component of delivering a complete customer experience platform," said Vlad Shmunis, founder, chairman, and CEO of RingCentral. "We will now be able to offer our RingCX customers integration with industry-leading WEM and CX automation solutions from Verint. As the landscape of customer engagement solutions rapidly evolves, we remain committed to equipping our customers with cutting-edge, AI-powered solutions that not only enhance support and increase productivity, but also significantly reduce costs."

17:09 EST QuidelOrtho says 'solid progress' executing business improvement initiatives - Says structuring the company as a "leaner, flatter organization." In "early phases" of cost improvement initiates which should improve margins in 2025. Comments taken from Q3 earnings conference call.

17:09 EST Ovintiv raises 2024 total production view to 583-587 MBOE/d from 570-580 MBOE/d - Sees 2024 CapEx $2.28B-$2.33B.

17:07 EST Unity names Jarrod Yahes CFO - Unity announced that Jarrod Yahes will join as SVP, Chief Financial Officer on January 1, 2025. His appointment comes on the heels of last week's hiring of Steve Collins, ex-CTO of King and Havok co-founder, as Unity's new Chief Technology Officer. Jarrod Yahes joins Unity from Shutterstock, where he has served as CFO for the past five years. He helped drive the company's portfolio expansion into 3D content, data monetization, and digital advertising while emphasizing revenue growth and profitability. Prior to Shutterstock, Jarrod was the CFO of Zeta Global, a marketing technology company. "We are thrilled to welcome Jarrod to Unity. His blend of operational rigor and growth orientation will be instrumental for Unity's next stage," said Matt Bromberg, CEO and President of Unity. "We've now solidified the leadership team that will drive Unity towards greater operational discipline, accelerated product innovation, and deeper relationships with our customers and the community."

17:04 EST Wheaton Precious Metals still sees 2024 production 550K-620K gold eq. oz. - Still expects 2024 production of 325K-370K gold oz., 18.5M-20.5M silver oz., and 12K-15K GEOs of other metals.

17:01 EST Olo, ezCater deepen partnership with new integration - Olo will launch a new menu integration with ezCater, the #1 food tech platform for workplaces in the US, to simplify catering menu management. As the newest addition to Olo and ezCater's long-standing partnership, the integration will automate menu updates across both tech platforms, saving restaurants valuable time by reducing the need for manual updates.

17:00 EST Vacasa says still do not anticipate reaching EBITDA profitability this year

16:56 EST Edward, Ludmila Smolyansky support Danone bid to acquire Lifeway Foods - On September 23, Danone (DANOY) proposed to acquire Lifeway Foods (LWAY) in a transaction valued at approximately $283M, offering $25 per share in cash. However, on November 6, the Lifeway Foods Board of Directors rejected the offer, instead adopting a "poison pill" limited shareholder rights plan. Edward and Ludmila Smolyansky, significant shareholders and members of Lifeway Foods' founding family, released the following statement in response: "For nearly four decades, we have fostered Lifeway's growth with careful attention to what is best for the company's future. Today, we strongly support Danone's offer, which represents a substantial premium over Lifeway's recent share price and reflects their confidence in the growing U.S. kefir market - a category we helped build from the ground up. As we approach one of most significant and closely watched earnings releases in Lifeway's history, we remain optimistic about the company's potential and believe that Danone's proposal presents a unique opportunity to enhance value for all shareholders. We encourage the Lifeway board to carefully and in good faith reconsider Danone's offer and seize this opportunity to deliver lasting value to shareholders, employees, and consumers. CEO Julie Smolyansky and the board need to focus on the tangible, lucrative offer in front of them, not on futile distractions that waste valuable time and resources. The longer they wait, the more money they will leave on the table, to the detriment of all."

16:54 EST KeyCorp lowers prime lending rate to 7.75% from 8%, effective November 8

16:51 EST Dynavax announces $200M share repurchase program - Dynavax Technologies announced its Board of Directors has authorized the repurchase of up to $200M of the company's common stock. The share repurchase program does not have an expiration date and Dynavax currently expects that purchases will be executed within a period of up to one year.

16:49 EST Sandstorm Gold sees 70,000-75,000 gold equivalent ounces for 2024 - Based on the company's existing streams and royalties and the year-to-date outperformance of gold prices relative to other commodities, attributable gold equivalent ounces for 2024 are forecasted to be between 70,000 and 75,000 ounces. The company's production forecast is expected to reach approximately 125,000 attributable gold equivalent ounces within the next five years, based solely on streams and royalties that the company has bought and paid for.

16:43 EST TaskUs up 7% at $16.64 after Q3 earnings beat and guidance

16:35 EST Rivian Automotive up 3% at $10.35 after Q3 results

16:34 EST Rivian Automotive enters into strategic supply agreement with LG Energy - Rivian is announcing a strategic supply agreement with LG Energy Solution to power its next-generation midsize electric vehicle platform, underpinning the company's R2 midsize SUV. Under the terms of the agreement, LGES will supply 4695 cylindrical battery cells to Rivian for its midsize platform. Within the first year of production, the batteries are expected to be manufactured at LGES' Queen Creek, Arizona plant, aligning with Rivian's focus on U.S. domestic manufacturing and IRA compliance.

16:33 EST Inspired Entertainment names James Richardson as new CFO - Inspired Entertainment appointed James Richardson as its new Chief Financial Officer, effective January 1, 2025. The company said, "James Richardson to the Inspired Entertainment team. James's extensive background in financial management and his proven track record of driving growth and operational excellence make him an ideal fit for our company as we continue to execute our strategic initiatives and deliver value to our shareholders."

16:31 EST Victory Capital raises quarterly dividend 7% to 44c per share - "Cash on the balance sheet was $188 million, up $69 million from the end of the second quarter. Our net leverage ratio declined to 1.7x due to growth in Adjusted EBITDA and our increased cash position. Additionally, the Board authorized another 7% increase in our quarterly cash dividend from $0.41 to $0.44 per share, which will be paid in December," said CEO David Brown.

16:29 EST EOG Resources board raises quarterly dividend 7% to 97.5c per share - The Board of Directors declared a dividend of $0.975 per share on EOG's common stock. The dividend will be payable January 31, 2025, to stockholders of record as of January 17, 2025. The new dividend represents an indicated annual rate of $3.90 per share, a 7% increase from the previous level. EOG has never suspended or reduced its regular dividend.

16:27 EST RLI Corp. announces two-for-one stock split - RLI Corp. announced its Board of Directors has declared a special cash dividend of $4.00 per share of common stock, which is expected to total approximately $183 million, and a regular quarterly cash dividend of $0.29 per share. In addition, the board announced a two-for-one stock split. Both dividends are payable on December 20, 2024, to shareholders of record as of November 29, 2024. The two-for-one stock split is for shareholders of record as of December 31, 2024, and will be effective and shares will be distributed on January 15, 2025. Shares will begin trading post-split on January 16, 2025. Both the regular and special dividends will be paid on the pre-split shares.

16:22 EST Equifax CEO Mark Begor to continue company leadership beyond 2025 - Equifax announced that Mark Begor will continue to serve as CEO beyond the current expiration of his employment agreement in 2025.

16:20 EST Nerdy reports Q3 Active Members up 1% y/y to 39.7K

16:20 EST Civitas Resources sees Q4 sales volumes 347-353 Mboe/d - Fourth quarter 2024 sales volumes are expected between 347 and 353 MBoe/d, and oil volumes are anticipated in a range of 162 to 166 MBbl/d, reflecting an increase in the DJ Basin and a decline in the Permian Basin. The DJ Basin increase is anticipated to benefit from Watkins production uplifts, and the Permian Basin decline reflects few new wells commencing production in the final quarter of the year. Capital expenditures in the fourth quarter are anticipated to be $245 to $295 million, as the Company anticipates running 4 drilling rigs (3 Permian, 1 DJ) and 1.5 completion crews (1 Permian, 0.5 DJ) on average during the period. The Company's free cash flow generated in the fourth quarter is anticipated to be its highest quarter for the year, which will further benefit shareholder returns and debt reduction.

16:18 EST Agilon Health cuts FY24 adjusted EBITDA to ($155M)-($135M) from ($60M)-($15)

16:11 EST Banco Santander lowers prime rate to 7.75% - Santander Bank, N.A. announced today it has lowered its prime rate from 8.00% to 7.75% effective November 7, 2024.

16:11 EST Li-Cycle announces $475M loan facility with Department of Energy - Li-Cycle announced that it has entered into an agreement for a loan facility of up to $475M through the U.S. Department of Energy Loan Programs Office's Advanced Technology Vehicles Manufacturing program. "This is the first DOE loan facility to be finalized for a lithium-ion battery materials recycling company, which further demonstrates Li-Cycle's important role in the U.S. battery materials supply chain as a domestic supplier of recycled critical battery materials. The entry by Li-Cycle into definitive documentation with the DOE follows the DOE's detailed technical, market, financial and legal due diligence. The DOE Loan Facility is expected to support the development of the Company's flagship Rochester Hub project, located in upstate New York," the company said.

16:07 EST Toast sees Q4 adjusted EBITDA $90M-$100M - Sees FY24 adjusted EBITDA $352M-$362M vs. prior view of $285M-$305M.

15:57 EST M&T Bank to decrease prime lending rate to 7.75% from 8% - Effective Friday, November 8, 2024, M&T Bank Corporation will decrease its prime lending rate from 8.00% to 7.75%.

14:49 EST Serina Therapeutics Inc trading halted, volatility trading pause

14:40 EST Fifth Third to decrease prime lending rate to 7.75% - Fifth Third Bank, National Association, announced it will decrease its prime lending rate to 7.75%, effective immediately.

14:00 EST Sky Quarry chief tells investors to look at scalability of business model

14:00 EST Sky Quarry tech can challenge established growth in two industries, CEO says

13:27 EST Zoomcar Holdings Inc trading halted, volatility trading pause

12:00 EST Diebold falls -17.8% - Diebold is down -17.8%, or -$8.87 to $41.02.

12:00 EST Wolfspeed falls -27.3% - Wolfspeed is down -27.3%, or -$3.74 to $9.97.

12:00 EST IonQ rises 34.3% - IonQ is up 34.3%, or $5.63 to $22.09.

11:55 EST Caesars Virginia announces opening date of December 12 - Caesars Virginia announces its opening date will be Thursday, Dec. 12. "The resort will welcome its first guests beginning at noon. Additional details on the opening festivities will be announced at a later date," the company stated. "We have worked diligently on creating a world-class resort that will offer all the luxurious and modern amenities expected from Caesars that will also serve as an economic driver for Danville and the surrounding region through employment and tourism. We're so proud of Caesars Virginia and look forward to welcoming guests on Dec. 12," added Barron Fuller, Regional President for Caesars Entertainment.

11:03 EST IBM selected as Fan Engagement, Data Analytics Partner for Scuderia Ferrari - IBM (IBM) has entered into a multi-year agreement with Ferrari (RACE) to become the official Fan Engagement and Data Analytics Partner of Scuderia Ferrari HP, the most renowned Formula 1 team, starting in 2025. IBM and Scuderia Ferrari HP will conceive, develop, and deliver world-class digital experiences to bring racing enthusiasts closer than ever to the racing team. IBM and Scuderia Ferrari HP will develop a fully reimagined mobile app to be unveiled during the 2025 season. This includes applying IBM's technology and consulting expertise to analyze and transform Ferrari's massive volume and variety of data - both current and historical - into custom insights, personalized content, and innovative features designed to supercharge the fan experience. IBM will also provide its new cutting-edge technology and data-driven solutions to increase speed and production.

10:56 EST Turkcell trading halted, news pending

10:42 EST Entain appoints Dafne Guisard as COO - Entain plc (GMVHF) announced that Dafne Guisard has been appointed to the new role of Chief Operations Officer, effective from January 13, 2025. Dafne joins from Kraft Heinz (KHC), where, as Chief Strategy, Transformation and Digital Officer, "she spearheaded the global ten-year growth strategy, developed new operational models, and drove digital transformation across all areas of the company. At Entain, Dafne will drive operational excellence, leading global strategic planning, the customer service organisation, and M&A integration," the company stated. Gavin Isaacs, Chief Executive Officer, Entain, said: "Dafne brings a wealth of experience in driving strategic growth and delivering transformation on a global scale. Her appointment will help place Entain at the leading edge of innovation, as well as strengthen the executive management team as we build on a period of stronger-than-expected revenue growth and key market expansion. Dafne will be a tremendous asset to Entain."

10:22 EST Adagene presents data on ADG126 at SITC Annual Meeting - Adagene announced data at the SITC 39th Annual Meeting, taking place in Houston, Nov. 6 - 10, 2024. The two poster presentations provide new insights on the increased therapeutic index for ADG126 and reinforce its clinical safety and efficacy profiles in combination with pembrolizumab including in advanced Metastatic Microsatellite-stable Colorectal Cancer. In the first poster, Deciphering Improved Clinical Therapeutic Index of Muzastotug, a Masked Anti-CTLA-4 SAFEbody over its Unmasked Form as Monotherapy or in Combination with anti-PD-1 Therapy , data demonstrate how the improved TI of ADG126 allows for higher and repeat dosing to unleash its efficacy to the maximum potential, while maintaining an improved safety profile. Analyses of the masked ADG126 SAFEbody and its unmasked version, ADG116, show the improved TI relative to commercially available anti-CTLA-4 therapies via enhanced epitope-dependent ADCC and T cell priming. By targeting the constitutively over-expressed CTLA-4 on T regulatory cells in the tumor microenvironment for potent CTLA-4 mediated intratumoral Treg depletion, ADG126 achieves tumor-specific targeting with minimal on-target off-tumor toxicities. Key highlights include: The unique epitope of ADG126 and its activated form drives species cross-reactivity enabling the same antibody to be used across mice, monkey and human studies, with a unified set of physiologically relevant parameters for population pharmacokinetic modeling. Analyses show a significantly higher and sustained steady state tumor-specific engagement of CTLA-4 with the masked ADG126, suggesting increased exposure in the TME and a stronger ADCC effect. New analyses show the seamless translation of preclinical PK analyses to clinical PK data, including: head-to-head comparison of ADG126 to ipilimumab in MC38 mice, a single dose of ADG126 showed a three-fold increased active drug exposure in homogenized tumor tissue samples at 10 mg/kg versus a single dose of ipilimumab at 1 mg/kg while maintaining similar plasma active drug exposures. A second analysis in the MC38 mice model showed two consecutive doses of ADG126 at 20 mg/kg increased the tumor cleaved and total PK versus a single dose, demonstrating continuous intratumoral cleavage of intact ADG126 and accumulation within the TME. This reflects the effectiveness of ADG126 repeat dosing to increase drug exposure within the TME, supporting its mechanism with CTLA-4 mediated intratumoral Treg depletion. The second poster, Phase 1b/2, Multicenter Dose Escalation and Expansion Study of Muzastotug in Combination with Pembrolizumab in Advanced/Metastatic MSS CRCs, presents additional follow up data from an ongoing trial showing the best-in-class therapeutic potential of ADG126 in combination with anti-PD-1 therapy in patients with the most common form of colorectal cancer, MSS CRC. The trial, conducted in patients with advanced MSS CRC without liver metastases, showed that ADG126 administered at 10 mg/kg Q6W or Q3W in combination with pembrolizumab demonstrated an encouraging efficacy signal, durable disease control and an early survival benefit in MSS CRC patients, with dose-dependent efficacy and objective responses per RECIST criteria observed for the Q3W schedule. New findings in the poster at SITC 2024 include: In MSS CRC patients, a lower rate of key TRAEs with ADG126 at the 10 mg/kg dosing level in combination with pembrolizumab relative to lower doses of 1-2 mg/kg of an Fc engineered anti-CTLA-4 antibody in clinical development when used in combination with anti-PD-1. Clinical PK, particularly the monitoring of active species of ADG126 in peripheral blood, supports long-term safety of the combination therapy. The rate of Grade 3 and higher TRAEs for ADG126 in combination with pembrolizumab was also shown to be much lower than historically reported with currently approved standard of care combinations. In the combination cohort, there was no Grade 3 or higher colitis, which is common with other anti-CTLA-4 therapies. A case study of one responder who received two prior lines of therapy before receiving ADG126 in combination with pembrolizumab showed an 80% decrease in target lesions. This confirmed partial response correlated with a 100% decrease in carcinoembryonic antigen levels versus baseline. Individualized PK data also demonstrated the correlation of tumor shrinkage and plasma exposure. After five cycles, the patient experienced TRAEs, after which dosing was modified and treatment resumed, showing durable clinical benefit for over 12 months. This response is one of four PRs reported from the ongoing 10 mg/kg Q3W combination cohort of MSS CRC patients without liver metastases. Repeat doses of ADG126 10 mg/kg in combination with pembrolizumab shows encouraging dose-dependent clinical efficacy and well-tolerated safety in accordance with plasma cleaved ADG126 concentrations. These data support that ADG126 may be a potential best-in-class anti-CTLA-4 and may be considered as a backbone therapy. Follow up continues for MSS CRC patients treated with ADG126 10 mg/kg doses in combination with pembrolizumab. In addition, Adagene is evaluating a single dose of ADG126 at 20 mg/kg followed by a 10 mg/kg Q3W maintenance dose in combination with pembrolizumab in a cohort of 12 enrolled patients with data expected in 2025.

10:18 EST Galaxy Payroll Group Ltd trading resumes

10:17 EST Imunon presents data from Phase 2 OVATION 2 clinical trial - IMUNON announced the presentation of new clinical data from the recently completed Phase 2 OVATION 2 Study of IMNN-001, its investigational interleukin-12 immunotherapy for the treatment of advanced ovarian cancer based on the company's proprietary TheraPlas technology. Results will be highlighted in a late-breaking poster session at the Society for Immunotherapy of Cancer 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas and virtually. IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local production and secretion of the IL-12 protein. IL-12 is one of the most active pluripotent cytokines for the induction of strong anti-cancer immunity acting through the induction of T-lymphocyte and natural killer cell proliferation, inhibiting tumor mediated immune suppression. A total of 112 patients with newly diagnosed advanced ovarian cancerwere enrolled in the Phase 2 OVATION 2 Study with a median follow-up of 24 months. Study participants were randomized 1:1 to evaluate the safety and efficacy of IMNN-001 plus neoadjuvant and adjuvant chemotherapy of paclitaxel and carboplatin compared to standard-of-care NACT alone. The results being presented at the SITC Annual Meeting, as of June 21, 2024, demonstrated: Patients treated with IMNN-001 plus standard-of-care NACT lived 11.1 months longer than patients treated with NACT alone with a median overall survival of 40.5 months and 29.4 months, respectively. IMNN-001 treatment was associated with better surgical outcomes compared to NACT alone with a surgical response rate of 64.6% and 52.1%, respectively. The chemotherapy response score, another measure of treatment benefit, was 26.1% in the IMNN-001 treatment group versus 13.0% in the control group. IMNN-001 was also associated with an improvement in progression-free survival with a median PFS of 14.9 months in the IMNN-001 treatment group compared to 11.9 months in the control group. The rate of complete response for best overall response, a measure of tumor shrinkage, was comparable across all study participants when measured early in the study at debulking surgery. In a subgroup analysis of patients who received a PARP inhibitor as maintenance therapy, patients in the IMNN-001 treatment arm had a median PFS of 33.8 months versus 22.1 months in the control arm and median OS was not reached for the treatment arm versus 37.1 months for the control arm. IMNN-001 was generally well tolerated, with the most common adverse events primarily gastrointestinal events. Pain management protocols were found to be effective. There were no reports of cytokine release syndrome or any other serious immune related AEs.

10:11 EST Allogene announces Phase 1 data on ALLO-316 in advanced RCC - Allogene Therapeutics will concurrently present new data from the Phase 1 TRAVERSE trial in an oral presentation at the 2024 International Kidney Cancer Symposium and a poster session at The Society for Immunotherapy of Cancer's Annual Meeting. The trial evaluates ALLO-316, the Company's first AlloCAR T product candidate for the potential treatment of solid tumors. The ongoing Phase 1 TRAVERSE trial is enrolling patients with advanced or metastatic renal cell carcinoma who have progressed following treatment with an immune checkpoint inhibitor and VEGF-targeting therapy. These presentations highlight compelling evidence of CAR T activity and anti-tumor efficacy in 26 patients with RCC tumors known to be CD70 positive who were evaluable for efficacy outcomes. As of the October 14, 2024 data cutoff, 39 patients had been enrolled in the ongoing Phase 1 trial, of which 26 were confirmed to have CD70 positive RCC and were evaluable for efficacy outcomes. The median time from enrollment to the start of therapy was five days. Data from dose escalation cohorts and ongoing Phase 1b expansion cohort are included in the presentations. The Phase 1b expansion cohort is evaluating safety and efficacy of ALLO-316 at DL2 following a standard FC500 lymphodepletion regimen. The Phase 1b expansion cohort is expected to ultimately include approximately 20 patients. Additional data from the Phase 1b expansion cohort is expected to be announced in mid-2025. Following a single infusion of ALLO-316 in heavily pretreated patients, the trial demonstrated best Overall Response Rate of 50% and Confirmed Response Rate of 33% in those patients with CD70 Tumor Proportion Score of greater than or equal to50% who received DL2. Patients with a TPS of greater than or equal to50% comprise the majority of patients with advanced or metastatic RCC. Of those with a TPS greater than or equal to50, 76% experienced a reduction in tumor burden. Two of six patients with high TPS who received the Phase 1b expansion regimen showed durable responses ongoing at greater than or equal to4 months. The most common all-grade adverse events were cytokine release syndrome, fatigue, neutropenia, decreased white blood cell count, anemia and nausea. Immune effector cell-associated neurotoxicity syndrome was minimal at 8% and no graft-versus-host disease occurred. TEAE included all AEs that started from the first dose date of study drug in each treatment period up to start of another treatment period, death, or the date prior to initiation of another anti-cancer agent, whichever occurred first. IEC-HS includes the preferred terms IEC-HS, HLH, Hemophagocytic lymphohistiocytosis, and atypical HLH. Two patients developed an inflammatory syndrome prior to the existence of IEC-HS as a term in MedDRA, which has been updated as of September 2023. Two DLT events of autoimmune hepatitis and cardiogenic shock were reported. Each event occurred in 2 separate participants who received FCA lymphodepletion and DL2 of ALLO-316. Three Grade 5 treatment-related adverse events were reported: 1) cardiogenic shock, which was one of the 2 DLT events; 2) sepsis from multi-drug resistant Klebsiella pneumoniae in a participant who received DL4 of ALLO-316. This participant had a prior episode of muscle abscess and bacteremia from the same multi-drug resistant Klebsiella and was receiving anakinra and dexamethasone for hyperinflammation; 3) failure to thrive in a participant 16 months after treatment with ALLO-316. This subject had tumor response of stable disease at month 12 and no interval scans to evaluate disease status prior to death.

10:08 EST Galaxy Payroll Group Ltd trading halted, volatility trading pause

10:06 EST Bolt Biotherapeutics presents updated preclinical data for BDC-4182 - Bolt Biotherapeutics presented updated preclinical data for BDC-4182, a next-generation Boltbody ISAC clinical candidate targeting claudin 18.2, and provided key learnings from its Phase 1 dose-escalation trial of BDC-1001 at the 39th Annual Meeting of the Society for Immunotherapy of Cancer, being held in Houston, Texas from November 6-10, 2024. BDC-4182 is a next-generation Boltbody ISAC clinical candidate targeting claudin 18.2, a clinically validated target in oncology with expression in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. BDC-4182 has advanced into IND-enabling activities, supported by in vitro and in vivo experiments demonstrating potent anti-tumor activity in multiple preclinical models, with clinical trial initiation expected in 2025. In vivo assessment of anti-tumor activity was performed with a murine surrogate of BDC-4182 using xenograft and syngeneic tumor models with different levels of claudin 18.2 expression. The tolerability of BDC-4182 was also tested in non-human primates. Key findings are summarized below: BDC-4182 demonstrated superior efficacy compared to cytotoxic claudin 18.2 ADCs. BDC-4182 demonstrated anti-tumor activity in a wide range of tumor models and elicits immunological memory. BDC-4182 has an acceptable safety profile in NHPs with findings consistent with TLR7/8 activation and claudin 18.2 targeting. BDC-4182 toxicology profile may enable combinations with checkpoint inhibitors, chemotherapy and anti-angiogenesis agents used in first-line and second-line treatments. Key learnings from the Phase 1 dose escalation trial of BDC-1001 are summarized below. First-generation ISAC BDC-1001 demonstrated immunological activity in this first-in-human trial, particularly in patients with high HER2 antigen expression. Greater immune activation was associated with clinical benefit. Pharmacodynamic changes were observed in HER2 IHC3+ and HER2 IHC2+, with both the greatest increase and statistical significance in patients with HER2 IHC 3+ tumors. Data supports the hypothesis that an ISAC with enhanced immune activation could offer greater efficacy, warranting further testing in next-generation ISACs.

10:00 EST Under Armour rises 27.8% - Under Armour is up 27.8%, or $2.44 to $11.19.

10:00 EST Dutch Bros rises 36.8% - Dutch Bros is up 36.8%, or $12.87 to $47.80.

10:00 EST Clear Secure falls -20.4% - Clear Secure is down -20.4%, or -$7.86 to $30.59.

09:58 EST Ralph Lauren says 'on track' with new store openings - Expects Q4 to be negatively impacted by a late Easter. Expects FY marketing as a percentage of sales roughly in-line with last year, lower in Q4. Says "pullback on promotion is the game plan." Feels "very good" about momentum in China. "Energized" about near and long-term growth prospects in China. Expects to open ~70 stores in Asia this year.

09:51 EST Contango Ore announces $12M cash distribution from Peak Gold JV - Contango ORE announced that the Peak Gold JV paid a cash distribution of $12.0 million on October 24, 2024. These proceeds relate to Contango's 30% of profits from the processing of Manh Choh ore from Campaign #2. In total, Contango has received $31.5 million in cash distributions from the Peak Gold JV since commencing the processing of Manh Choh ore in July 2024. The Peak Gold JV has completed two campaigns with a third campaign currently underway. Contango's 30% share of production from Campaigns #1 and #2 totals approximately 30,000 ounces of gold with a further 8,500 ounces of gold expected from Campaign #3 for total production in 2024 of approximately 38,500 ounces of gold.

09:47 EST LifeStance Health Group trading halted, volatility trading pause

09:47 EST Clear Secure falls -21.5% - Clear Secure is down -21.5%, or -$8.25 to $30.20.

09:47 EST Under Armour rises 18.1% - Under Armour is up 18.1%, or $1.58 to $10.33.

09:47 EST Dutch Bros rises 31.7% - Dutch Bros is up 31.7%, or $11.07 to $46.01.

09:41 EST Jianzhi Education announces advancements in natural language processing - Jianzhi Education Technology Group Company announced major advancements that will expand adoption of its educational offerings, and accelerate developers' abilities to build highly accurate educational content for the next evolution of AI-based education. The new offerings include AI models that can generate educational content using NLP. "The generative AI boom for education is here," said Hu Yong, CEO of Jianzhi. "Now, with the enhancements and accessibility Jianzhi is bringing to AI-based education, educators of all kinds can build virtual worlds to drive innovation while preparing for the next wave of AI-based education."

09:38 EST ENDRA Life Sciences Inc trading resumes

09:37 EST Tetra Tech awarded $30M contract - Tetra Tech announced that the Utah Army National Guard awarded Tetra Tech a five-year, single-award contract not to exceed $30 million. The watershed-focused restoration and resiliency contract will support its Camp Williams training site.

09:36 EST Hyperfine announces CE approval of Swoop system software - Hyperfine announced CE approval of its latest generation of AI-powered Swoop system software under the European Medical Device Regulation. This approval marks a step in positioning Hyperfine for broad European launch of the Swoop Portable MR Imaging system, enabling faster, high-quality MR brain imaging that supports critical diagnostic decisions across diverse healthcare settings.

09:35 EST Pros Holdings appoints Colleen Langevin as chief marketing officer - Pros Holdings announced the appointment of Colleen Langevin as chief marketing officer, or CMO. Langevin brings more than 20 years of experience. As CMO, Langevin will lead Pros global marketing organization and strategy, with a focus on scaling the demand generation engine as well as driving the next phase of digital marketing transformation.

09:33 EST AxoGen trading halted, volatility trading pause

09:31 EST Top KingWin's Guji achieves RMB 2M in October revenue - Top Kingwin announced that its subsidiary, Guji Technology has achieved a significant milestone by generating RMB 2million in revenue in October 2024.

09:31 EST TeleTech trading halted, volatility trading pause

09:29 EST Gilead to present HIV research findings at conference - Gilead announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, taking place from November 10-13. The results from more than 40 studies across HIV treatment and prevention include late-breaking data and seven oral presentations. These findings reflect a robust portfolio and future-looking pipeline focused on person-centered drug development strategies to address unmet needs in HIV and help end the epidemic. A late-breaking oral presentation at HIV Glasgow will be the first in-depth look at the full results from the PURPOSE 2 trial, including data not presented last month at the HIV Research for Prevention Conference in Lima, Peru. PURPOSE 2 is a pivotal Phase 3 trial evaluating twice-yearly lenacapavir, Gilead's injectable HIV-1 capsid inhibitor for the investigational use of HIV prevention, among a broad and geographically diverse range of cisgender men and gender-diverse people. The trial is part of a comprehensive program assessing lenacapavir in a variety of populations who need or want pre-exposure prophylaxis and, if approved, would be the first and only twice-yearly HIV prevention choice. Prevention research presented at HIV Glasgow will also include a systematic review and meta-analysis of real-world data mapping HIV prevalence against PrEP uptake, health economic data on the impact of PrEP in France and the return on investment that HIV prevention has yielded for the French healthcare system. Data will also be presented from a study examining same-day PrEP initiation and its effect on PrEP uptake at a Canadian clinic. Continuous scientific discovery in HIV treatment is a pillar of Gilead's commitment to help end the epidemic. At HIV Glasgow, presented study results and analyses will include further evaluation of Biktarvy as a long-term treatment option for a broad range of people with HIV who may also have common comorbidities and other specific health needs. Outcomes from pipeline research studies will provide insights into investigational treatment candidates, including the novel combination regimen of lenacapavir plus bictegravir. Additionally, late-breaking data from the Phase 2 study evaluating an investigational once-weekly oral combination regimen of lenacapavir and islatravir will be presented during an oral session. Specifically, Biktarvy presentations will include four-year outcomes from BICSTaR, an ongoing global, observational, real-world study evaluating the effectiveness, safety, and tolerability of Biktarvy in treatment-naive and treatment-experienced people with HIV who have a high burden of co-morbidities. As the average age of people with HIV increases, the management of comorbid conditions is an important consideration in HIV clinical care. BICSTaR helps to inform what the future of coordinated person-centered HIV care could look like. Additional research studies evaluating Biktarvy include three-year outcomes from ALLIANCE, an ongoing Phase III study evaluating the efficacy and safety of the single-tablet regimen versus dolutegravir 50 mg + emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg, F/TDF, DTG+F/TDF, in adults with HIV/hepatitis B coinfection who were initiating therapy. Gilead will also present outcomes from the Phase 2 portion of the ARTISTRY-1 study investigating the efficacy and safety of switching from a complex stable baseline regimen to an investigational once-daily regimen of lenacapavir and bictegravir. Additional lenacapavir data to be presented at HIV Glasgow will evaluate the efficacy and safety of the novel antiviral agent in combination with broadly neutralizing antibodies teropavimab and zinlirvimab as a potential long-acting treatment regimen with twice-yearly dosing. HIV treatment research pipeline findings also include a presentation of new pharmacokinetic and resistance data on GS-1720, a selective integrase strand transfer inhibitor. The agent is being evaluated as a component of a novel, investigational, once-weekly oral INSTI/capsid-inhibitor combination regimen with GS-4182 aimed at providing new long-acting treatment options for people with HIV. A late-breaker presentation will compare the rate of treatment emergent resistance associate mutations in people with HIV taking three-drug single tablet regimens and cabotegravir+rilpivirine. A separate late-breaker oral presentation will explore clinical features and resistance patterns during second-generation INSTI failure from the ROSETTA-registry.

09:23 EST CEL-SCI, FDA agree on patient selection approach for Multikine study - CEL-SCI announced that in a recent meeting the FDA concurred with the company's approach to patient selection using low PD-L1 tumor expression in its confirmatory registration study for Multikine. This study will focus on the treatment of newly diagnosed locally advanced primary head and neck cancer patients with no lymph node involvement and low PD-L1 tumor expression. This registration study, slated to commence in the first quarter of 2025, will enroll approximately 212 patients and prospectively confirm the favorable safety profile and the very favorable efficacy results demonstrated in the target population in CEL-SCI's prior Phase 3 randomized study of 928 patients.

09:22 EST Warner Bros. Discovery says on track to exceed $1B streaming EBITDA in 2025

09:21 EST Oklo completes environmental compliance process for INL power plant site - Oklo announced that the U.S. Department of Energy, or DOE, and the Idaho National Laboratory, or INL, have completed the environmental compliance process addressing the DOE requirements for site characterization at Oklo's first commercial advanced fission power plant site at INL. This process, resulting in an Environmental Compliance Permit, marks a milestone as Oklo advances its plans to deliver the first commercial advanced fission power plant in the United States. This announcement follows the recent finalization of a memorandum of agreement with the DOE, which initiates site characterization activities. It also comes on the heels of the DOE approval of Oklo's Conceptual Safety Design Report for its Aurora Fuel Fabrication Facility, which will recycle nuclear material at INL to fuel the Aurora powerhouse.

09:19 EST Xilio Therapeutics announces initial data from Phase 1C trial for XTX101 - Xilio Therapeutic announced initial clinical data from its ongoing Phase 1C clinical trial evaluating vilastobart, a tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, in combination with atezolizumab in patients with advanced solid tumors. The data will be presented in a late-breaker poster presentation on November 8, 2024, at the Society for Immunotherapy of Cancer, SITC, 39th Annual Meeting taking place in Houston, Texas.

09:17 EST IonQ announces partnership with NKT Photonics - IonQ announced a partnership with NKT Photonics, a subsidiary of Hamamatsu Photonics, to procure next-generation laser systems for IonQ's trapped-ion quantum computers and networking equipment. The partnership involves NKT Photonics developing and delivering three prototype optical subsystems to IonQ in 2025, designed to support the commercialization of IonQ's data center-ready quantum computers - such as IonQ Tempo and future barium-based systems.

09:16 EST Fat Brands' Hurricane Grill & Wings open at Six Flags Great Escape Lodge - Hurricane Grill & Wings, owned by FAT Brands (FAT), announce the opening of a new location at Six Flags (FUN) Great Escape Lodge, Lake George's premier family resort destination. As the hotel's brand-new, flagship dining option, the restaurant brings a vibrant, laid-back atmosphere with delicious menu offerings to both resort guests and the Lake George regional community.

09:15 EST Nutanix expands partnership with Amazon Web Services - Nutanix (NTNX) announced an expanded strategic collaboration with Amazon (AMZN) Web Services to accelerate cloud migration and provide options for customers managing workloads across on-premises and cloud environments. This aims to reduce the friction required for IT modernization, making it easier for customers to leverage AWS services to drive innovation.

09:13 EST Clearside Biomedical's partner signed new collaboration agreement with Santen - Clearside Biomedical (CLSD) announced today that the Company's Asia-Pacific partner, Arctic Vision, has signed a new commercial collaboration agreement with Santen Pharmaceutical (SNPHY) for ARVN001, branded in the U.S. as XIPERE, for the treatment of uveitic macular edema and certain other ophthalmic indications under development. Under the terms and conditions of the agreement, Arctic Vision has granted the rights of ARVN001 to Santen to commercialize the product candidate in China excluding Taiwan, Hong Kong and Macau. XIPERE for suprachoroidal use was developed by Clearside and is currently being sold in the United States by Bausch + Lomb.

09:10 EST Xilio Therapeutics expects cash to fund operations into Q2 of 2025 - Based on its current operating plans, Xilio anticipates that its existing cash and cash equivalents as of September 30, 2024, will be sufficient to fund its operating expenses and capital expenditure requirements through the end of the second quarter of 2025.

09:09 EST Gravity reports results of Rangarok IP launches - Gravity announced that since the official launching of The Ragnarok in 10 regions of Southeast Asia and Ragnarok: Rebirth in Taiwan, Hong Kong and Macau on October 31, The Ragnarok has ranked first in free download of Google Play in 6 regions of Thailand, Indonesia, Philippines, Malaysia, and Singapore, and ranked second in free download of Apple App Store in 4 regions of Thailand, Indonesia, Philippines and Malaysia after pre-download on October 29. After its launching, the game ranked third in top grossing of Google play in Thailand and Philippines, and ranked first in Philippines and second in Thailand and Indonesia in top grossing of Apple App Store. Ragnarok: Rebirth has ranked second in Hong Kong and Macau, and third in Taiwan in free download of Google Play, and ranked first in free download of Apple App Store in Taiwan, Hong Kong and Macau after pre-download on October 29. It has ranked second in Macau, seventh in Taiwan and eighth in Hong Kong in top grossing of Apple App Store, and ranked fifth in top grossing of Google Play in Macau after its launching.

09:07 EST Stran & Company secures six-figure agreements with leading customers - Stran & Company has secured significant six-figure agreements, collectively expected to generate more than $2 million in sales annually, with three industry-leading customers. The first agreement was signed with a leading national developer, acquirer, and operator of high-quality rental communities. Stran was selected for its extensive range of product and service offerings, bolstered by a strong track record of success. A key factor in Stran's selection was its advanced technology platform, which provides centralized access to essential marketing and branding assets, empowering the client to drive their brand presence seamlessly. The second agreement is with a molecular diagnostics company specializing in cancer prevention, detection, and treatment solutions. Stran's technology and scalable warehousing capabilities were instrumental in winning this contract. The client also recognized Stran's creative expertise while appreciating the Company's preparedness and comprehensive service approach. In the third agreement, Stran was chosen by a global public transportation services provider to enhance their branding efforts with innovative promotional merchandise. Under the agreement, Stran will provide promotional merchandise branding services. Stran's strong reputation, reliability, and tailored product solutions were significant factors in this selection, further underscoring the Company's commitment to delivering creative and impactful marketing solutions.

09:05 EST Zevia expands distribution of Better-For-You soda in Walmart stores - Zevia (ZVIA) is expanding its Walmart (WMT) distribution this month from +800 stores to now being available nationally in over 4,300 locations, an increase of more than five-times current store distribution. The partnership includes Walmart expanding the Better-for-You soda category, resulting in Walmart's new in-store set "Modern Soda." Zevia Soda in Walmart has seen growth in existing Walmart stores over the past two years, with consumers consuming 4x more Zevia products per household versus competition. The Better-for-You soda category is growing overall and just recently reached $1B in sales.

09:02 EST Werewolf Therapeutics sees cash runway through 2Q26 - As of September 30, 2024, cash and cash equivalents were $122.8 million, compared to $135.3 million as of June 30, 2024. The Company believes its existing cash and cash equivalents as of September 30, 2024, will be sufficient to fund operational expenses and capital expenditure requirements through at least the second quarter of 2026.

08:57 EST Gaucho Group announces milestone in wine sales performance - Gaucho Group announced a significant milestone in its wine sales performance. For the year to date in 2024, the Company's sales have increased by 185% compared to the same period in 2023, coupled with an impressive 40% increase in the average sales price per bottle. This growth in both volume and pricing is the result of strategic initiatives by the Company's wine brand, Algodon Fine Wines, aimed at refining its distribution tactics and enhancing brand positioning within the market. The increased average sales price reflects the successful enhancement of the perceived value of Algodon's wine products, driven by quality improvements and premium branding efforts. These results mark the infancy stages of a new strategic push in the Company's ecommerce direct-to-consumer channels in Argentina, and supported by traditional importer, distribution networks, and retail models in the United States. This phase comes after substantial investments in production capacity and the expansion of the Company's winery in San Rafeal, Mendoza, Argentina. Recent enhancements include new French oak barrels, additional stainless-steel tanks, and a state-of-the-art bottling and labeling machine. These upgrades are critical to Algodon's strategy to manage increased production while maintaining the high-quality standards for which its wines are known.

08:56 EST PureCycle Technologies provides Q3 corporate update - PureCycle Technologies announced a corporate update for the third quarter ending September 30, 2024. PureCycle CEO Dustin Olson commented, "The third quarter represented meaningful progress for the Company on multiple fronts. The Company has significantly improved our rates, reliability, and product quality at Ironton. While there is still more work to be done, we are confident in continuing to move the Ironton Facility forward and pursuing nameplate capacity targets in the future. These achievements are allowing the Company to turn its focus toward the next phase of PureCycle's growth by ramping-up our commercialization efforts." Olson continued, "With positive customer feedback and initial success in commercial trials, Q3 was a pivotal time for the team. We are seeing strong interest in our product by leading companies from several market channels and plan to increase production to meet those needs. The Company believes this should lead to meaningful sales going into 2025." As previously announced, the Ironton Facility hit three key production milestones before the end of the third quarter, including one million pounds of feedstock processed in a week; 200,000 pounds of feedstock processed in a day; and feed rates of more than 10,000 pounds per hour. Each of these targets was set with a focus on proving out specific elements of the plant. With the facility having shown greater reliability and uptime, the Company can focus on ramping toward nameplate capacity and improving product quality. The equipment updates to the co-product 2 removal system have been commissioned and are working as designed. In addition to the CP2 removal improvements, the Company advanced its sorting strategy in mid-October by commissioning a new 325,000 square foot facility located in Denver, Pennsylvania. The facility sorts mixed plastic bales using optical and robotic sorting technologies. With these technologies, the facility has been able to improve the polypropylene concentration of the mixed bales from ~60-80% to ~90-95%. The higher concentration of polypropylene combined with the improved CP2 removal system has led to greater output and improved quality at the Ironton Facility. The market continues to lack high quality recycled material and PureCycle offers an answer for companies looking to achieve their sustainability goals. Initial feedback from customers in the qualification process has been very positive and the Company is working to convert these trials into orders in the near future. The Company has produced and built meaningful inventory to meet near term expected demand and give customers confidence Ironton will be able to ramp-up to meet their needs. The increased production volume at the Ironton Facility and expanded efforts with compounding allowed the Company to introduce samples to new markets and further trials with potential customers. PureCycle recently provided The Procter & Gamble Company with compounded material. This will allow P&G to begin the approval process for the recycled resin in various applications. PureCycle plans to provide material to P&G for production beginning in Q2 or Q3 of 2025. The Company completed multiple trials with customers in the fiber market, which has been an underserved area when it comes to recycled polypropylene. These trials were conducted with some of the largest fiber manufacturers in the country and built upon earlier smaller-scale successful trials. PureCycle worked with the manufacturers to produce continuous filament and staple fibers with varying product properties that should allow for the introduction into applications such as carpet, clothing, upholstery, and automotive. The Company also progressed the approval process with one of the largest global automotive manufacturers for both interior and exterior applications. The first application would include PureCycle resin from 100% recycled feedstock.

08:53 EST Warner Bros. Discovery: Stock price does not reflect underlying value of company

08:52 EST SMX, FinGo enter collaboration mandate to develop 'Phyiscal to Digital' platform - SMX announces its collaboration mandate with Sthaler Ltd, which markets FinGo ID, a cutting-edge Human Identity SaaS. Together, they intend to develop a centralized reporting platform to ensure transparency within the artisanal and small-scale mining sector, and through the entire supply chain to ensure all ASM gold exported comes from an ethical and responsible source. According to the World Bank, one widely used estimate is that more than 100 million people globally depend either directly or indirectly on ASM for their livelihoods. SMX believes the global marketplace for ASM gold is becoming increasingly complex, and the global gold market faces rising regulatory pressure to comply with stringent environmental, social, and governance regulations. It further believes that governments are under pressure to ensure that all gold exports are ethical, compliant with government regulations, and able to report evidential data accurately in real time. This collaboration mandate is the first step in a planned broader relationship between SMX and Sthaler expected to address: Ethical sourcing of precious metals; Child labour; Use of chemicals; Location identification of artisanal miners and mining operations

08:50 EST Workhorse Group secures multiple orders for W56 electric step vans - Workhorse Group announced it has secured purchase orders from three parcel delivery independent service providers for its W56 step vans. The new orders, received in the 30 days following the Company's participation at FedEx Forward Service Provider Summit, are for seven W56 electric trucks for parcel delivery, including both the standard 178" wheelbase and the new 208" extended wheelbase. All vehicles are scheduled for delivery by the end of the year.

08:49 EST Modular Medical announces results from GLP-1 PoC study - Modular Medical announced results from its pre-clinical GLP-1 proof of concept study. "We are excited by the results of this pre-clinical, proof of concept study in a standard obese mouse model," stated Dr. David Maggs, M.D., medical advisor for this study. "We used a rapid-acting GLP-1 with a short half-life delivered by pump at a continuous basal rate, with several treatment arms adding a moderate additional bolus, just once a day, at the start of the feeding cycle. At the highest basal-bolus dose, we saw a 17.1% weight loss at 28 days compared to 13.7% with basal alone at the same dose, despite the short half-life of bolus GLP-1. We believe this profound effect strongly suggests that a pump delivered basal-bolus GLP-1 could bring weight and glucose benefits similar to or beyond those observed with long-acting and basal-only GLP-1 treatment modalities. A pump-delivered GLP-1 may also offer dosing flexibility for those patients sensitive to GI issues common among currently available GLP-1s. All dosing variations of the rapid-acting GLP-1 outperformed semaglutide in controlling blood glucose excursion after a standard glucose challenge, with the basal-bolus combinations performing the best." As expected, none of the rapid acting GLP-1 arms matched the overall weight loss effect of the semaglutide arm. Notably, however, the semaglutide treated mice lost 8% of their body weight in the first two days of treatment as food and water intake was almost entirely absent. The rapid acting GLP-1 pump-treated mice had a much smoother initiation of treatment, as measured by body weight and food and water intake. "With these encouraging results, we are now planning to take this concept of a synergistic basal-bolus GLP-1 combination into a human trial using our MODD1 device. We are considering both existing fast acting GLP-1s and other peptides for this trial, as we see this as a platform technology that could be used for more personalized titration for both non-responder or non-adherent patients experiencing GI and other issues with long acting GLP-1s, as well as for other specialty applications in metabolic therapies. This type of application is well suited for our MODD1 pump, given its quick training time, simple interface, high accuracy at low flow rates, reusable low-cost electronics, and a prefill-capable 3mL reservoir," stated Jeb Besser, CEO of Modular Medical.

08:47 EST Volatus Aerospace appoints Greg Colacitti as COO - Volatus Aerospace announced the appointment of Omar Mourad, CFA, Director, Private Equity - Manufacturing & Diversified Product with Investissement Quebec, to the Board of Directors. Omar brings extensive expertise in private equity and strategic investment, aligning with Volatus' vision for expansion and industry leadership. Volatus is pleased to announce that Greg Colacitti has been promoted to the position of COO, replacing Steve Magirias, who is no longer with the Company. Greg, who has been with Drone Delivery Canada since 2014, most recently served as Director of Operations and is a co-inventor on all Drone Delivery Canada patents. His leadership approach and alignment with Volatus' post-merger objectives make him well-suited to support the Company's continued growth. As previously announced, Rob Walker, will continue as Chief Commercial Officer. Volatus is also pleased to report that phase one of the post-merger integration of Volatus Aerospace Corp and Drone Delivery Canada is complete ahead of schedule. This progress supports the Company's aggressive efforts to commercialize its proprietary technologies and remote operations capabilities, enabling Volatus to deliver an increasingly comprehensive range of aerial solutions to clients worldwide.

08:46 EST Perma-fix Environmental announces completion of Perma-FAS system - Perma-Fix Environmental Services announces the successful completion of the fabrication, installation, commissioning, and startup of its first full-scale commercial Perma-FAS system for PFAS destruction at the Company's Perma-Fix Florida facility. This landmark development in Perma-Fix's PFAS treatment technology marks a significant step forward in the safe, energy-efficient destruction of PFAS, commonly known as "forever chemicals."

08:45 EST Pieris Pharmaceuticals announces first patient dosed in SELVA Phase 3 trial - Palvella Therapeutics announced the first patient has been dosed in SELVA, a multicenter, Phase 3 clinical trial designed to evaluate the safety and efficacy of QTORIN 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations. "We are pleased to have dosed the first patient in our Phase 3 SELVA trial, an important milestone towards our objective of advancing QTORIN rapamycin to potential regulatory approvals and U.S. commercialization," said Wes Kaupinen, Founder and Chief Executive Officer of Palvella. "QTORIN rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for the estimated more than 30,000 diagnosed patients suffering from microcystic LMs in the U.S."

08:43 EST Mustang Bio granted Orphan Drug Designation by U.S. FDA for MB-108 - Mustang Bio announced that the U.S. Food and Drug Administration, FDA, has granted Orphan Drug Designation to Mustang for MB-108, a herpes simplex virus type 1 oncolytic virus, for the treatment of malignant glioma. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, "The Orphan Drug Designation for MB-108 is significant for Mustang, as it could provide additional market exclusivity and we hope to advance MB-108, in combination with MB-101, as a potential treatment option for patients living with malignant glioma, including patients with recurrent glioblastoma and high-grade astrocytomas, where there is historically a median overall survival of six months. Our novel therapeutic strategy, combining our MB-108 oncolytic virus with MB-101 CAR-T cell therapy, could be the first-ever industry-sponsored trial of its kind for the treatment of malignant glioma. As such, Mustang plans to also request Orphan Drug Designation from the FDA for MB-101 in malignant gliomas. These advancements highlight our dedication to potentially improving outcomes for patients battling difficult-to-treat cancers."

08:41 EST FuelCell announces 1-for-30 reverse stock split - FuelCell Energy announced that a 1-for-30 reverse stock split of its issued and outstanding shares of common stock will become effective at 5:00 p.m., Eastern time, on November 8, 2024, and that trading of the Company's common stock on a post-split basis on The Nasdaq Global Market is expected to begin on November 11, 2024.

08:40 EST ePlus and Digital Realty launch AI experience center - ePlus (PLUS) and Digital Realty (DLR) announced a partnership to launch a state-of-the-art AI Experience Center to be hosted in Digital Realty's Innovation Lab located in Ashburn, VA. Designed to help accelerate an organization's AI journey, the AI Experience Center will enable customers to experience AI technologies in data center facilities purpose-built for AI-optimized infrastructure. Hosting the AI Experience Center inside of Digital Realty's Innovation Lab enables customer access to public and private cloud environments via ServiceFabric. Additionally, customers can orchestrate AI-specific workloads across Digital Realty's Private AI Exchange. In addition to the technology demonstrations at the facility, customers can also take advantage of the suite of ePlus AI Ignite assessments and workshops.

08:39 EST Saratoga Investment board declares special dividend of 35c per share - Saratoga Investment Board of Directors has declared a base quarterly dividend of $0.74 per share for the fiscal third quarter ending November 30, 2024, and an additional special dividend of $0.35 per share fulfilling our fiscal 2024 distribution requirements. Both dividends are payable on December 19, 2024, to all stockholders of record at the close of business on December 4, 2024.

08:37 EST Neurocrine's Ingrezza shows efficacy in Huntington's Disease Chorea - Neurocrine Biosciences presented subgroup analyses and data from the KINECT-HD study showing the impact of Iingrezza - valbenazine - capsules on emotional health and psychiatric stability in patients with chorea associated with Huntington's disease. The subgroup analysis showed consistent efficacy in reducing chorea compared to placebo across all identified subgroups, categorized by demographics and baseline assessment scores. A separate data analysis showed improvements in some aspects of emotional health with no worsening of psychiatric symptoms.

08:36 EST Banzai reports preliminary Q3 adjusted EBITDA ($1.4M) - Preliminary, unaudited Q3 2024 Adjusted Net Loss was approximately ($0.9) million, a $3.6 million sequential improvement from Q2 2024 Adjusted Net Loss of ($4.5) million. This represents an annualized improvement of $14.5 million. "In the third quarter of 2024 we achieved preliminary, unaudited historic record NRR, and strong improvements from the second quarter in both ARR and adjusted Net Income," said Joe Davy, Founder and CEO of Banzai. "We are making significant progress against our annualized goals through our recently launched comprehensive initiative designed to significantly improve Net Income while maintaining our growth outlook. We look forward to providing additional updates at our conference call and quarter financial results on November 14."

08:35 EST Nature's Miracle launches EV business in U.S. and South America - Nature's Miracle's 100% owned subsidiary Hydroman will become Hydroman Electric. In conjunction with this update, Hydroman Electric will launch a new business and strategic pivot focusing on marketing and distribution of electric-powered agriculture vehicles and commercial vehicles throughout the U.S. and South America. This development is accretive to the company's previously announced agreement with Robostreet in which Nature's Miracle will order approximately 150 electric trucks and broader initiative to diversify its business in the electrification economy.

08:33 EST MDU Resources raises 2024 earnings view for regulated energy delivery business - Now sees 2024 earnings guidance for its regulated energy delivery businesses to $180M-$185M from $170M-$180M.

08:31 EST Datadog 'mindful' some customers may optimize cloud and observability usage - On the company's earnings call, Datadog executives stated: "While we believe that adoption of ROI will continue to benefit Datadog in the long term, we are mindful that some of the large customers in this cohort have ramped extremely rapidly, and that these customers may optimize cloud and observability usage and increase their commitments to us over time with better terms. This may create volatility in our revenue growth in future quarters."

08:29 EST Enlight Renewable announces power purchase agreement for Snowflake A Project - Enlight Renewable Energy announces that its U.S. subsidiary Clenera has signed a new power purchase agreement, PPA, with Arizona Public Service, APS, for its Snowflake A Project. The busbar fixed price PPA encompasses the Project's 600 MW of solar generation capacity and 1900 MWh of energy storage availability, and is for a duration of 20 years. "This marks a major steppingstone for Clenera and Enlight in Arizona," said Adam Pishl, CEO of Clenera. "We have spent years working with local and state regulators to design a project that fits the location, makes excellent use of the land, and will be a generational benefit to the region. Our engagement with the community has been very positive and I look forward to delivering a new source of clean energy to APS ratepayers."

08:27 EST Warner Bros. Discovery seeing 'strong momentum' in DTC business - Expects momentum to continue in Q4. Expects to use all free cash flow to retire debt.

08:27 EST Enhabit appoints Ryan Solomon as CFO - Enhabit announced the appointment of Ryan Solomon as its next CFO, effective Dec. 9. Solomon's appointment follows the previously announced transition of Crissy Carlisle, CFO. Solomon brings to Enhabit over 20 years of corporate strategy and finance experience, including eight years as CFO in the home health and hospice space and other industries.

08:24 EST Intra-Cellular to present at 2024 Psych Congress, NEI Congress - Intra-Cellular Therapies announced presentations about lumateperone including the results from Phase 3 adjunctive Major Depressive Disorder Studies 501 and 502 at Psych Congress held October 29- November 2 in Boston and Neuroscience Education Institute Congress being held November 7-10 in Colorado Springs. Studies 501 and 502 demonstrated robust efficacy of lumateperone as an adjunctive therapy to antidepressants for the treatment of MDD. In the primary endpoint, the Montgomery-Asberg Depression Rating Scale total score, lumateperone demonstrated a large separation versus placebo of 4.9 points in Study 501 and 4.5 points in Study 502 with robust effect sizes of 0.61 and 0.56 respectively. This efficacy was confirmed in both studies not only by the primary endpoint, the MADRS total score, but also by the strong results in the clinician rated Clinical Global Impression Scale for Severity of Illness scale and the patient reported Quick Inventory of Depressive Symptomatology Self-Report scale. CAPLYTA's efficacy results were complemented with a favorable metabolic, weight and movement disorder profile. In the adjunctive MDD setting these data present a compelling clinical profile for lumateperone in the treatment of MDD. These results further support the Company's vision for CAPLYTA to become a leading option for patients and providers across mood disorders.

08:23 EST Regency Centers raises quarterly dividend 5.2% to 70.5c per share - Regency Centers announced that the Company's Board of Directors declared quarterly cash dividends on Regency's common stock, Series A preferred stock, and Series B preferred stock. On November 5, 2024, the Board declared a quarterly cash dividend on the Company's common stock of $0.705 per share, representing an increase of $0.035 per share, or 5.2%, from the prior quarterly dividend. The dividend is payable on January 3, 2025, to shareholders of record as of December 16, 2024. On November 5, 2024, the Board declared a quarterly cash dividend on the Company's Series A preferred stock of $0.390625 per share. The dividend is payable on January 31, 2025, to shareholders of record as of January 16, 2025. On November 5, 2024, the Board declared a quarterly cash dividend on the Company's Series B preferred stock of $0.367200 per share. The dividend is payable on January 31, 2025, to shareholders of record as of January 16, 2025.

08:21 EST Indaptus Therapeutics completes safety, PK, biomarker data on Decoy20 - Indaptus Therapeutics announces compelling safety, pharmacokinetics, PK, and biomarker data on its lead compound, Decoy20, at the Society for Immunotherapy of Cancer, SITC, 2024 annual meeting. The data derive from two cohorts of Decoy20 single administration and one cohort (6 patients) of Decoy20 weekly administration in the Company's ongoing Phase 1 clinical trial. The SITC conference is being held November 6-10, 2024 in Houston, Texas. The data presented demonstrated that Decoy20 administered intravenously once weekly mainly showed side effects that were classified as mild or moderate and transient in duration. Further, pharmacokinetic analysis confirmed that Decoy20 quickly disappeared from the bloodstream after administration, supporting the Company's "pulse" approach. One patient in the trial who has squamous cell carcinoma of the head and neck with high levels of PD-L1, which is a protein that is associated with tumor response to certain immunotherapies, had "stable disease" - meaning the cancer had not progressed or worsened - at the time of their first imaging scan.

08:21 EST Sunrise Realty Trust announces closing of senior revolving credit facility - Sunrise Realty Trust announced the closing of a new senior secured revolving credit facility with East West Bank serving as agent and the initial lender. The Revolving Credit Facility provides access up to $200 million in borrowing capacity, subject to available borrowing base and additional commitments, with an initial commitment of $50 million. With favorable terms, including an interest rate of SOFR plus 2.75%, the Revolving Credit Facility offers SUNS flexibility to borrow and repay funds as needed. This facility strengthens SUNS' ability to pursue strategic growth initiatives and capitalize on high-quality investment opportunities across the Southern United States.

08:19 EST LakeShore Biopharma initiates BLA submission to DRAP for PIKA rabies vaccine - LakeShore Biopharma announced the initiation of its Biologics License Application submission to the Drug Regulatory Authority of Pakistan for the conditional approval of its PIKA rabies vaccine for post-exposure prophylaxis. This submission is based on the results that met the primary endpoints of the vaccine's global pivotal trial and demonstrated the vaccine's potential to achieve accelerated protection and meet the WHO's goal of a one-week rabies vaccine regimen to replace the conventional three- or four-week regimens. The PIKA Rabies Vaccine, which utilizes LakeShore Biopharma's proprietary PIKA adjuvant technology based on Toll-like receptor 3 immunological pathway, is designed to produce a more robust immune response in an accelerated timespan compared to existing rabies vaccines. It was granted orphan drug designation by the US FDA for prevention of rabies virus infection including post-exposure prophylaxis for rabies. The pivotal registration Phase 3 Trial was a randomized, comparator-controlled, double-blind, multicenter trial which includes 4,500 participants from the Philippines and Pakistan. It is designed to assess the immunogenicity, safety, and lot-to-lot consistency of three lots of the PIKA Rabies Vaccine in healthy adults using a 7-day vaccine schedule, versus a globally marketed comparator following the standard 28-day regimen. The primary immunogenicity endpoints of the study were geometric mean titers of rabies virus neutralizing antibodies and RVNA seroconversion rate at Day 14 in the first 900 participants. This accelerated and higher seroconversion rate came at no cost to safety, with the safety profile of the PIKA Rabies Vaccine remaining highly tolerable.

08:18 EST The Buckle reports October 2024 comparable sales up 0.6% year over year - October net sales increased 0.1% to $87.9M from $87.8M for October 2023. Comparable store net sales for the 13-week third quarter ended November 2, 2024 decreased 0.7% from comparable store net sales for the 13-week period ended November 4, 2023.

08:17 EST Annovis Bio appoints Peterson as Senior Clinical Scientist - Annovis Bio announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson will be responsible for medical, ethical, and scientific quality and rigor in the initiation, conduct, reporting, and successful completion of Annovis' clinical trials.

08:15 EST Genasys announces four-year contract with Los Angeles County - Genasys announced a four-year contract with Los Angeles County for Genasys ALE mass notification software services. LA County's successful use of Genasys EVAC, EVAC, emergency evacuation management services since 2022 led to the County's decision to replace its previous mass notification provider with ALERT to enhance public safety for the county's 9.8 million residents and 50 million annual visitors during wildfires and other disasters.

08:14 EST Aspira Women's Health expands collaboration with Bioreference - Aspira Women's Health (AWH) announced the expansion of its co-marketing and distribution collaboration with BioReference Health, a wholly-owned subsidiary of OPKO Health. (OPK), a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets. Under the terms of the expanded agreement, Aspira and BioReference will join forces to market Aspira's complete OvaSuite portfolio, including OvaWatch(R) and Ova1Plus, to BioReference women's healthcare provider clients. BioReference and Aspira have co-marketed and distributed Ova1Plus since 2022. The approval of OvaWatch by the New York State Department of Health's Clinical Laboratory Evaluation Program (CLEP) in early October paved the way for the expanded relationship by making it available to the 15+ million women in New York and New Jersey.

08:12 EST Third Harmonic Bio sees cash runway through at least 2026 - Cash and cash equivalents totaled $296.1 million as of September 30, 2024. Based on the Company's current operating plan, Third Harmonic Bio believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements through at least 2026.

08:11 EST SpringWorks Therapeutics' ogsiveo shows long-term efficacy in Phase 3 trial - SpringWorks Therapeutics announced that long-term efficacy and safety data from the Phase 3 DeFi trial of nirogacestat in adults with progressing desmoid tumors will be presented as a late-breaking oral presentation at the Connective Tissue Oncology Society 2024 Annual Meeting November 13-16 in San Diego, CA. These results, utilizing an August 2024 data cutoff date, showed that longer-term treatment with nirogacestat was associated with further reductions in tumor size, increase in objective response rate with additional partial responses and complete responses, sustained improvements in desmoid tumor symptoms including pain, and a consistent safety profile compared to the April 2022 data cut utilized for the primary results of the trial.

08:09 EST LiveOne continues process to explore strategic alternatives - As previously announced with the assistance of J.P. Morgan, LiveOne is continuing a process to explore strategic alternatives to enhance shareholder value. Potential alternatives may include, among others, a strategic acquisition, divestiture, merger, sale or other form of business combination. There can be no assurance that LiveOne's efforts will result in a specific transaction or any particular outcome or its timing.

08:07 EST MBX Biosciences sees cash runway into mid-2027 - As of September 30, 2024, MBX had cash, cash equivalents and marketable securities of $277.1 million compared to $80.7 million as of December 31, 2023. Based on its current operating plan, management expects the combined cash, cash equivalents and marketable securities balance to fund operations into mid-2027.

08:05 EST Extreme Networks deepens partnership with NHL - Extreme Networks announced that it has deepened its partnership with the NHL. As a result, several NHL clubs, including the Anaheim Ducks, Calgary Flames, Columbus Blue Jackets and Nashville Predators, have deployed Extreme solutions to enhance in-arena Wi-Fi connectivity.

08:03 EST BorgWarner says Joseph Fadool to replace Frederic Lissalde as CEO - BorgWarner (BWA) announced that its Board of Directors approved a leadership succession plan whereby Joseph Fadool, BorgWarner's Executive Vice President and COO, has been appointed President and CEO and a member of BorgWarner's Board of Directors effective at the close of business on February 6, 2025. At that time, Frederic Lissalde will retire from his role as President and CEO and step down from the Board of Directors. To support a seamless transition, Lissalde will serve in an advisory role until August 30, 2025. Joseph Fadool joined BorgWarner in 2010 and has held a number of top positions across the company, including COO and President and General Manager of Emissions, Thermal and Turbo Systems, Morse Systems and TorqTransfer Systems, the precursor to PowerDrive Systems. Prior to joining BorgWarner, Fadool worked at Continental Automotive Systems as Vice President for North American Electronic Operations and at Ford Motor Company (F).

08:03 EST Quoin Pharmaceuticals continues to evaluate M&A opportunities - The company said, "Quoin is committed to advancing its clinical programs and remains focused on expanding the potential indications for QRX003. The company's efforts in initiating clinical studies in additional rare disease indications, such as Peeling Skin Syndrome, and expanding its global clinical footprint for Netherton Syndrome trials are crucial steps in Quoin's strategy to bring new treatments to patients with serious unmet needs. The Company continues to evaluate M&A opportunities within the rare and orphan disease space as part of its long-term growth strategy."

08:01 EST Geron announces $375M in synthetic royalty, debt financings with Royalty Pharma - Geron (GERN) announced up to $375M in synthetic royalty and debt financings with Royalty Pharma (RPRX) and investment funds managed by Pharmakon Advisors, of which $250M in cash was provided at closing and another $125M in debt is available. The transactions are comprised of a $125M synthetic royalty with Royalty Pharma and $250M of committed senior secured debt with investment funds managed by Pharmakon Advisors. Royalty Pharma has provided $125M at closing and will receive tiered royalty payments on U.S. net sales of Rytelo, ranging from 7.75% of annual net sales up to $500M, 3% of annual net sales between $500M and $1B, and 1% of annual net sales over $1B. Payments to Royalty Pharma will cease if the aggregate royalties payable through June 30, 2031, reach a multiple of 1.65 its investment, otherwise the royalty payments will continue until Royalty Pharma receives a multiple of 2.0 its investment. There are no other royalties payable on Rytelo, which was developed internally and is exclusively owned by Geron.

07:57 EST Palantir, Anthropic announce partnership with Amazon Web Services - Anthropic and Palantir Technologies (PLTR) announced a partnership with Amazon Web Services (AMZN) to provide U.S. intelligence and defense agencies access to the Claude 3 and 3.5 family of models on AWS. This partnership allows for an integrated suite of technology to operationalize the use of Claude within Palantir's AI Platform while leveraging the security, agility, flexibility, and sustainability benefits provided by AWS. The partnership facilitates the responsible application of AI, enabling the use of Claude within Palantir's products to support government operations such as processing vast amounts of complex data rapidly, elevating data driven insights, identifying patterns and trends more effectively, streamlining document review and preparation, and helping U.S. officials to make more informed decisions in time-sensitive situations while preserving their decision-making authorities. Claude became accessible within Palantir AIP on AWS earlier this month. With Palantir's AIP, customers can now operationalize Claude using an integrated suite of technology, facilitated by Amazon SageMaker, an accredited fully managed service, and hosted on Palantir's Impact Level 6 accredited environment, supported by AWS. Palantir and AWS are among a limited number of companies to receive the Defense Information Systems Agency IL6 accreditation requiring some of the strictest security protocols.

07:57 EST ZenaTech participates in a Trade Mission to Taipei, Taiwan - ZenaTech announces that company principals are currently participating in a Trade Mission to Taipei, Taiwan as part of an Arizona Commerce Authority, ACA, delegation, with the goal of opening a manufacturing office for its previously announced Spider Vision Sensors Ltd. subsidiary. This subsidiary will manufacture drone sensors and components to be integrated with ZenaDrone multifunction autonomous AI drones, manufactured at company facilities in Sharjah, UAE, and future facilities in Phoenix, Arizona. ZenaTech's CEO and CTO are in Taiwan finalizing manufacturing office facilities, meeting with potential partners, and completing registration tasks to establish and open this company in November.

07:56 EST Proxy advisory firms tell News Corp. shareholders vote for Starboard proposal - Starboard Value, one of the largest shareholders of News Corp. announced that Institutional Shareholder Services, or ISS, Glass, Lewis, and Egan-Jones, three U.S. proxy advisory firms, recommend shareholders vote for Starboard's proposal to collapse the dual-class share structure at the company's upcoming 2024 Annual Meeting of Shareholders. Additionally, Ownership Matters Governance Advisors, a proxy advisory firm in the Australian market, recommends shareholders vote for this same proposal.

07:55 EST CalciMedica name Stephen Bardin as CFO - CalciMedica announced the appointment of Stephen Bardin as CFO and the planned departure of Daniel Geffken, Interim CFO upon filing the company's third quarter financial statements. Bardin brings extensive capital raising, corporate development, and strategic finance expertise to CalciMedica, having most recently served as CFO of atai Life Sciences.

07:54 EST Next Hydrogen Solutions to demonstrate electrolyzers for aviation industr - Next Hydrogen Solutions (NXHSF) is developing high-efficiency, low-cost electrolyzers needed for establishing hydrogen production infrastructure for the aviation industry. Pratt & Whitney Canada will demonstrate hydrogen combustion technology on a PW127XT regional turboprop engine under the project named Hydrogen Advanced Design Engine Study. Pratt & Whitney is an RTX (RTX) business. This project is supported by Canada's Initiative for Sustainable Aviation Technology. Funding for the first phase of the project will include fuel nozzle and combustor rig testing using hydrogen fuel, while future phases will target full engine ground testing. The PW127XT engine is the most advanced member of Pratt & Whitney Canada's PW100 engine series, which has powered regional turboprop aircraft for forty years and accumulated more than 220 million flight hours. Launched in 2021, the PW127XT engine offers over 3% better fuel efficiency, 40% improved time on wing, and 20% reduced maintenance costs.

07:52 EST Altimmune announces successful completion of End-of-Phase 2 meeting - Altimmune announced the successful completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration, FDA, and agreement on the design of a Phase 3 registrational program for its product candidate, pemvidutide, in the treatment of obesity. "Our interactions with the FDA regarding the Phase 3 development program have been incredibly productive, and this regulatory alignment represents a major accomplishment for our team," said Vipin K. Garg, Ph.D., Chief Executive Officer of Altimmune. "As the metabolic landscape continues to evolve, we believe that the ability of a drug to address both obesity and its underlying comorbidities will become increasingly important, and we are confident that this is where pemvidutide has an opportunity to excel. Achieving this regulatory milestone is especially important as we advance our partnering efforts, approach the data readout from our Phase 2b IMPACT Trial in MASH and prepare IND submissions for additional indications."

07:52 EST Draganfly to participate in ElevateUAV - Draganfly announces its participation in the upcoming ElevateUAV event, scheduled for November 12-14, 2024, at the FIU Kovens Conference Center in Miami, Florida. Hosted by Drone Nerds, ElevateUAV 2024 offers a three-day education program, live flight demonstrations, and networking with industry innovators who are propelling advancements in UAV technology. Attendees will have the opportunity to engage with leading technology providers and explore the latest trends in drone automation and integration. Draganfly will deliver hands-on training to Drone Nerds' operators, focusing on two flagship platforms: the Flex FPV and the Commander 3XL. These sessions aim to equip operators with the skills needed to maximize the potential of Draganfly's platforms in real-world applications.

07:50 EST Fidelity National raises quarterly dividend 4% to 50c from 48c per share - Fidelity National Financial announced that its Board of Directors has declared an increase in the company's quarterly cash dividend of 4% to 50c per common share from the previous quarterly cash dividend of 48c per common share. The dividend will be payable December 31 to stockholders of record as of December 17.

07:49 EST iSpecimen releases cancer biospecimen offering - iSpecimen announced a significant enhancement to its searchable inventory that provides researchers with increased access to a wide array of biospecimens vital to advancing oncology research and treatments. The expanded inventory includes highly sought-after cancer samples across a variety of tumor types, stages, and patient demographics, enabling researchers to access the specific samples they need efficiently and by cancer type, including colorectal, breast, lung, ovarian, pancreatic, brain, and more. By streamlining the acquisition of specific, high-quality biospecimens, iSpecimen is shortening sales and fulfillment timelines, increasing profitable revenue and supporting breakthroughs in cancer research, including studies focused on the development of new therapies, diagnostics, and personalized medicine approaches.

07:49 EST ParaZero securede $187,000 purchase order for drone safety systems - ParaZero Technologies recently announced that it has received a $187,000 purchase order from a U.S.-based Advanced Air Mobility, AAM, company in the aerial vehicle industry. This order, which was initially announced in September 2024, followed the successful completion of the advanced drone safety system customization project that the Company previously announced and marks another milestone for ParaZero in the growing air mobility sector. The purchase order included preparations for serial production, as well as the delivery of an initial batch of systems, signifying the initiation of potential future large-scale manufacturing and deployment of ParaZero's cutting-edge drone safety solutions

07:47 EST Lifecore to host virtual investor day on November 21 - Lifecore Biomedical announced that it will host a virtual investor day on Thursday, November 21, 2024, prior to market open. The event will take place from 8:00 - 9:30 a.m. Eastern Time and be available via webcast. During the event, members of Lifecore's senior management team will discuss the company's business and strategy for growth in the future, among other topics.

07:46 EST U.S. Cellular to sell select spectrum assets to AT&T for $1.018B - United States Cellular (USM) has announced that it has entered into an agreement with AT&T (T) to sell a portion of the company's retained spectrum licenses for total consideration of $1.018B. The transaction is part of the objective UScellular announced on May 28 to opportunistically monetize the spectrum that was not included in the proposed sale to T-Mobile (TMUS); and follows the transactions previously announced on October 18 to sell a portion of the retained spectrum licenses to Verizon (VZ) and two other mobile network operators, the company noted. Following this transaction, as well as those previously announced, UScellular will have reached definitive agreements to monetize approximately 55%, measured on a MHz-Pops basis, of the spectrum holdings, excluding mmWave, that were excluded from the proposed sale to T-Mobile, for a total consideration of approximately $2.02B. Including the proposed T-Mobile transaction, UScellular will have reached agreements to monetize approximately 70% of its total spectrum holdings, excluding mmWave, measured on a MHz-Pops basis. "We are pleased with the significant value that will be realized in the various transactions recently announced," said Laurent Therivel, President and CEO. "This agreement adds a fourth mobile network operator, in addition to T-Mobile, to the list of those whose subscribers will benefit from the sale of our spectrum licenses. As with the other mobile network operators, we are confident that AT&T can put it to productive use in communities throughout the U.S. Furthermore, the terms of the agreement will ensure that there will be continued, uninterrupted service for UScellular customers in the interim. After our proposed sales, we will be left with 1.86 billion MHz-Pops of low and mid-band spectrum, as well as 17.2 billion MHz-Pops of mmWave spectrum, with the substantial majority of retained value in the C-band spectrum."

07:45 EST Green Thumb Industries opens RISE Orlando dispensary - RISE Dispensaries announced the opening of RISE Dispensary Orlando on Good Homes Road on Friday, November 8. Located at 725 Good Homes Road, the new West Orlando location expands RISE Dispensaries' retail footprint in Florida to 21 locations and 99 nationwide. Beginning November 8, RISE Dispensary Orlando on Good Homes Road will offer patients high-quality, award-winning products and best-in-class service, including home delivery. RISE Dispensary Orlando on Good Homes Road will welcome patients Monday through Saturday from 9 a.m. to 8 p.m. and Sunday from 11 a.m. to 6 p.m. and encourage them to explore the location's broad selection of curated products, including RYTHM premium flower, concentrate and full spectrum vapes, Dogwalkers pre-rolls, Good Green flower, Doctor Solomon's tinctures and &Shine flower, pre-rolls, vapes and chews.

07:44 EST SpringBig announces official entry into gaming industry - Springbig (SBIG) announced its official entry into the gaming industry, offering its SMS solutions to skilled gaming apps, casinos, sports betting platforms, horse tracks, betting advice sites, and more. This expansion is powered by a new strategic partnership with Amazon Web Services (AMZN), enabling Springbig to provide unmatched marketing capabilities to these high-demand sectors. As the sports betting industry continues to grow and evolve, effective customer engagement becomes more crucial than ever. Since the gaming industry is considered a regulated industry, achieving reliable text message deliverability can be challenging without a partner experienced in supporting regulated sectors-one who offers both the expertise and support to ensure the success of every text message marketing campaign. Springbig's innovative SMS platform ensures that gaming companies can connect with their audiences more effectively, delivering messages with exceptional reliability and impact. Springbig's entry into the gaming sector began with a collaboration with a major player in the skilled gaming industry that was facing challenges with message delivery. After integrating with Springbig's platform, the merchant quickly saw significant improvements in their marketing performance: Improved Delivery Rates: Game Story achieved a 90% message delivery rate with Springbig, ensuring their marketing messages effectively reached their audience. Increased CTR: With reliable message delivery, Game Story saw their click-through rate rise to an impressive 15%. Reduced Costs: The cost per re-engagement dropped from over $100 to just $15, showcasing the cost efficiency of Springbig's SMS campaigns. Additionally, Game Story experienced an 80% lower Cost Per Purchase, further enhancing their return on investment. Boosted Profitability: Game Story reported a 250%+ Return on Ad Spend within just 7 days of using Springbig's solution, highlighting the significant impact on their profitability. Increased Paying Customers: In July alone, 3,265 paying customers returned to Game Story by sending SMS campaigns powered by Springbig.

07:40 EST Cingulate sees cash runway into 3Q25 - As of September 30, 2024, Cingulate had approximately $10 million in cash and cash equivalents, a significant increase from December 31, 2023, providing the Company with an extended cash runway into the third quarter of 2025.

07:36 EST Dogwood says cash 'not sufficient' to fund requirements for next 12 months - The Company estimates that its current cash of $2.0 million at September 30, 2024 along with the $16.5 million in loan proceeds received on October 7, 2024 is not sufficient to fund operating expenses and capital requirements for at least the next 12 months. The Company will need to secure the additional $3.0 million of loan proceeds available to us under the terms of the loan agreement in February 2025 to continue to fund our operations through 2025.

07:29 EST Cogent increases quarterly dividend to 99.5c per share - On November 6, Cogent's board approved a regular quarterly dividend of 99.5c per share payable on December 6 to shareholders of record on November 22. This fourth quarter regular dividend represents an increase of 1c per share, or 1%, from the third quarter regular dividend of 98.5c per share and an annual increase of 4.2% from the fourth quarter 2023 dividend of 95.5c per share.

07:23 EST Evergy increases quarterly dividend 4% to 66.75c per share - The Board of Directors declared a dividend on the Company's common stock of $0.6675 per share payable on December 20, 2024. The dividends are payable to shareholders of record as of November 21, 2024.

07:11 EST Rapport Therapeutics adds new members to Board of Directors - The Company announced the appointment of new members to its Board of Directors to help guide its next phase of growth and innovation, including Rob Perez, operating partner at General Atlantic and former chief executive officer of Cubist Pharmaceuticals; Raymond Sanchez, MD, former chief medical officer of Cerevel Therapeutics; Paul Silva, former chief accounting officer at Vertex Pharmaceuticals; and Wendy B. Young, PhD, former head of small molecule drug discovery at Genentech. With these appointments, Jeff Tong, PhD, partner at Third Rock Ventures, has resigned from the Board of Directors.

07:06 EST MoonLake Immunotherapeutics sees cash runway into end of 2026 - Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable debt securities, expected to support a roadmap rich in potential catalysts and a cash runway to the end of 2026

07:05 EST Marex Group sees FY24 adjusted operating profit $300M-$305M - Due to the strong performance in the third quarter, the company anticipates its Adjusted Operating Profit to be approximately $300 million to $305 million for the full year ending 31 December 2024 (previously $280 million to $290 million).

07:02 EST Cullinan Therapeutics sees cash runway into 2028 - Cash, cash equivalents, short- and long-term investments, and interest receivable were $639.0 million as of September 30, 2024. Cullinan continues to expect its cash resources to provide runway into 2028 based on its current operating plan.

06:46 EST PG&E increases capital investment plan by $1B - The company said, "PG&E Corporation is increasing its 5-year capital investment plan by $1 billion for a total of $63 billion for 2024 through 2028. The incremental capital is driven by growing customer demand and has already been approved by the California Public Utilities Commission through Decision 24-07-008. The incremental capital has also already been financed through the recent issuance of junior subordinated notes and PG&E Corporation is reaffirming its 2025 to 2028 equity issuance guidance of $3 billion."

06:43 EST Moderna sees 2024 filings for next-gen COVID, RSV vaccines - Moderna intends to file in 2024 for approval of its next-generation COVID-19 vaccine, mRNA-1283, and RSV vaccine, mRNA-1345, for high-risk adults aged 18-59, the company stated. "The company expects to communicate the PDUFA date for each of these programs when it is confirmed. Moderna intends to use priority review vouchers for mRNA-1283 and mRNA-1345 for high-risk adults aged 18-59. For its flu/COVID combination vaccine, mRNA-1083, the company intends to file in 2024, subject to ongoing discussions with the U.S. FDA, and has decided not to use a priority review voucher," Moderna stated.

06:25 EST Freshworks to reduce staff by 13% in restructuring plan - In a regulatory filing, the company said, "In November 2024, the company committed to a restructuring plan to better align the company's talent with its strategic priorities and to improve operating efficiency. The company estimates that this will result in approximately 13% reduction in headcount and approximately $11M to $13M in charges in the fourth quarter of 2024, consisting primarily of cash expenditures for separation-related payments, employee benefits and related costs. The company expects that the Plan will be substantially complete by the end of the fiscal year ending December 31, 2024."

06:14 EST Mega Matrix streaming flatform enters pact with PT Multimedia Nusantara - Mega Matrix announced that its short drama streaming platform, FlexTV, recently signed a two-year cooperation agreement with PT Multimedia Nusantara. This agreement was brokered by AR Asia Productions.

06:07 EST LandBridge declares 10c per share quarterly dividend - The company announced an initial 10c per share cash dividend, payable on December 19 to shareholders of record as of December 5.

05:50 EST Flex LNG secures time charter extensions - Flex LNG announced it has agreed with the charterer of Flex Courageous and Flex Resolute, a Supermajor, to amend the existing time charter agreements, or TC, for the two LNG carriers where the parties have agreed a new firm period from 2029 to 2032 which may be extended by an additional seven years in total until 2039.

05:46 EST CRH increases quarterly dividend to 35c per share - The board has declared a quarterly dividend of 35c per share. This represents an annualized increase of 5% on the prior year. The dividend will be paid wholly in cash on December 18 to shareholders registered at the close of business on November 22. The ex-dividend date will be November 22.

05:24 EST STMicroelectronics enters 21-year PPA with Engie SA entity and Conextone Energy - STMicroelectronics (STM) announced a 21-year power purchase agreement, or PPA, with BKH Solar Sdn Bhd, an entity jointly established by Engie Renewable (ENGIY) and Conextone Energy. The agreement will facilitate the supply of approximately 50 GWh of renewable energy annually from a new solar farm in Bukit Kayu Hitam, Kedah, Malaysia. This long-term agreement is undertaken under the Corporate Green Power Program introduced by the Malaysian Single Buyer in 2023.

05:13 EST Ceva expands share repurchase program with additional 700,000 shares - Furthermore, the Ceva board of directors authorized the expansion of the company's share repurchase program with an additional 700,000 shares of common stock available for repurchase, bringing the total shares available for repurchase to approximately 1M.